Y. Barak, D. Liao, W. He, E. Ong, M. Nelson et al., Effects of peroxisome proliferator-activated receptor ?? on placentation, adiposity, and colorectal cancer, Proceedings of the National Academy of Sciences, vol.99, issue.1, pp.303-308, 2002.
DOI : 10.1073/pnas.012610299

G. Barish, V. Narkar, and R. Evans, PPAR??: a dagger in the heart of the metabolic syndrome, Journal of Clinical Investigation, vol.116, issue.3, pp.590-597, 2006.
DOI : 10.1172/JCI27955

F. Briand, S. Naik, I. Fuki, J. Millar, C. Macphee et al., Both the Peroxisome Proliferator-Activated Receptor ?? Agonist, GW0742, and Ezetimibe Promote Reverse Cholesterol Transport in Mice by Reducing Intestinal Reabsorption of HDL-Derived Cholesterol, Clinical and Translational Science, vol.108, issue.2, pp.127-133, 2009.
DOI : 10.1111/j.1752-8062.2009.00098.x

A. Bugge, L. Grøntved, M. Aagaard, R. Borup, and S. Mandrup, The PPAR??2 A/B-Domain Plays a Gene-Specific Role in Transactivation and Cofactor Recruitment, Molecular Endocrinology, vol.23, issue.6, pp.794-808, 2009.
DOI : 10.1210/me.2008-0236

A. Chawla, C. Lee, Y. Barak, W. He, J. Rosenfeld et al., PPAR?? is a very low-density lipoprotein sensor in macrophages, Proceedings of the National Academy of Sciences, vol.100, issue.3, pp.1268-1273, 2003.
DOI : 10.1073/pnas.0337331100

U. Dressel, T. Allen, J. Pippal, P. Rohde, P. Lau et al., The Peroxisome Proliferator-Activated Receptor ??/?? Agonist, GW501516, Regulates the Expression of Genes Involved in Lipid Catabolism and Energy Uncoupling in Skeletal Muscle Cells, Molecular Endocrinology, vol.17, issue.12, pp.2477-2493, 2003.
DOI : 10.1210/me.2003-0151

E. Ehrenborg and A. Krook, Regulation of Skeletal Muscle Physiology and Metabolism by Peroxisome Proliferator-Activated Receptor ??, Pharmacological Reviews, vol.61, issue.3, pp.373-393, 2009.
DOI : 10.1124/pr.109.001560

P. Escher, O. Braissant, S. Basu-modak, L. Michalik, W. Wahli et al., Rat PPARs: Quantitative Analysis in Adult Rat Tissues and Regulation in Fasting and Refeeding, Endocrinology, vol.142, issue.10, pp.4195-4202, 2001.
DOI : 10.1210/endo.142.10.8458

E. Girroir, H. Hollingshead, P. He, B. Zhu, G. Perdew et al., Quantitative expression patterns of peroxisome proliferator-activated receptor-??/?? (PPAR??/??) protein in mice, Biochemical and Biophysical Research Communications, vol.371, issue.3, pp.456-461, 2008.
DOI : 10.1016/j.bbrc.2008.04.086

F. Gonzalez and Y. Shah, PPAR??: Mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators, Toxicology, vol.246, issue.1, pp.2-8, 2008.
DOI : 10.1016/j.tox.2007.09.030

T. Graham, C. Mookherjee, K. Suckling, C. Palmer, and L. Patel, The PPAR?? agonist GW0742X reduces atherosclerosis in LDLR???/??? mice, Atherosclerosis, vol.181, issue.1, pp.29-37, 2005.
DOI : 10.1016/j.atherosclerosis.2004.12.028

B. Gross and B. Staels, PPAR agonists: multimodal drugs for the treatment of type-2 diabetes, Best Practice & Research Clinical Endocrinology & Metabolism, vol.21, issue.4, pp.687-710, 2007.
DOI : 10.1016/j.beem.2007.09.004

B. Gross, J. Fruchart, and B. Staels, Peroxisome Proliferator-Activated Receptor ??/??: A novel target for the reduction of atherosclerosis, Drug Discovery Today: Therapeutic Strategies, vol.2, issue.3, pp.237-243, 2005.
DOI : 10.1016/j.ddstr.2005.08.009

H. Higashiyama, A. Billin, Y. Okamoto, M. Kinoshita, and S. Asano, Expression profiling of Peroxisome proliferator-activated receptor-delta (PPAR-delta) in mouse tissues using tissue microarray, Histochemistry and Cell Biology, vol.277, issue.5, pp.485-494, 2007.
DOI : 10.1007/s00418-007-0279-5

W. Huang, J. Zhang, P. Wei, W. Schrader, and D. Moore, Meclizine Is an Agonist Ligand for Mouse Constitutive Androstane Receptor (CAR) and an Inverse Agonist for Human CAR, Molecular Endocrinology, vol.18, issue.10, pp.2402-2408, 2004.
DOI : 10.1210/me.2004-0046

S. Hummasti and P. Tontonoz, The Peroxisome Proliferator-Activated Receptor N-Terminal Domain Controls Isotype-Selective Gene Expression and Adipogenesis, Molecular Endocrinology, vol.20, issue.6, pp.1261-1275, 2006.
DOI : 10.1210/me.2006-0025

H. Keller, P. Devchand, M. Perroud, and W. Wahli, PPAR? structure-function relationship derived from species-specific differences in responsiveness to hypolipidemic agents, Biol Chem, vol.378, pp.651-655, 1997.

F. Lalloyer, T. Pedersen, B. Gross, S. Lestavel, S. Yous et al., Rexinoid Bexarotene Modulates Triglyceride but not Cholesterol Metabolism via Gene-Specific Permissivity of the RXR/LXR Heterodimer in the Liver, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.29, issue.10, pp.1488-1495, 2009.
DOI : 10.1161/ATVBAHA.109.189506
URL : https://hal.archives-ouvertes.fr/inserm-00410108

C. Lee, K. Kang, I. Mehl, R. Nofsinger, W. Alaynick et al., Peroxisome proliferator-activated receptor ?? promotes very low-density lipoprotein-derived fatty acid catabolism in the macrophage, Proceedings of the National Academy of Sciences, vol.103, issue.7, pp.2434-2439, 2006.
DOI : 10.1073/pnas.0510815103

S. Lee, T. Pineau, J. Drago, E. Lee, J. Owens et al., Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators., Molecular and Cellular Biology, vol.15, issue.6, pp.3012-3022, 1995.
DOI : 10.1128/MCB.15.6.3012

P. Lefebvre, G. Chinetti, J. Fruchart, and B. Staesl, Sorting out the roles of PPAR?? in energy metabolism and vascular homeostasis, Journal of Clinical Investigation, vol.116, issue.3, pp.571-580, 2006.
DOI : 10.1172/JCI27989DS1

J. Luo, J. Quan, J. Tsai, C. Hobensack, C. Sullivan et al., Nongenetic mouse models of non???insulin-dependent diabetes mellitus, Metabolism, vol.47, issue.6, pp.663-668, 1998.
DOI : 10.1016/S0026-0495(98)90027-0

E. Kallwitz, A. Mclachlan, and S. Cotler, Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease, World Journal of Gastroenterology, vol.14, issue.1, pp.22-28, 2008.
DOI : 10.3748/wjg.14.22

K. Morimura, C. Cheung, J. Ward, J. Reddy, and F. Gonzalez, Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor ?? to Wy-14,643-induced liver tumorigenesis, Carcinogenesis, vol.27, issue.5, pp.1074-1080, 2006.
DOI : 10.1093/carcin/bgi329

D. Muoio, P. Maclean, D. Lang, S. Li, J. Houmard et al., Fatty Acid Homeostasis and Induction of Lipid Regulatory Genes in Skeletal Muscles of Peroxisome Proliferator-activated Receptor (PPAR) ?? Knock-out Mice: EVIDENCE FOR COMPENSATORY REGULATION BY PPAR??, Journal of Biological Chemistry, vol.277, issue.29, pp.26089-26097, 2002.
DOI : 10.1074/jbc.M203997200

A. Nagy, Cre recombinase: The universal reagent for genome tailoring, genesis, vol.22, issue.2, pp.99-109, 2000.
DOI : 10.1002/(SICI)1526-968X(200002)26:2<99::AID-GENE1>3.0.CO;2-B

W. Oliver, . Jr, J. Shenk, M. Snaith, C. Russell et al., A selective peroxisome proliferator-activated receptor ?? agonist promotes reverse cholesterol transport, Proceedings of the National Academy of Sciences, vol.98, issue.9, pp.5306-5311, 2001.
DOI : 10.1073/pnas.091021198

J. Peters, S. Lee, W. Li, J. Ward, O. Gavrilova et al., Growth, Adipose, Brain, and Skin Alterations Resulting from Targeted Disruption of the Mouse Peroxisome Proliferator-Activated Receptor beta (delta ), Molecular and Cellular Biology, vol.20, issue.14, pp.5119-5128, 2000.
DOI : 10.1128/MCB.20.14.5119-5128.2000

R. Raffaï and K. Weisgraber, Hypomorphic Apolipoprotein E Mice: A NEW MODEL OF CONDITIONAL GENE REPAIR TO EXAMINE APOLIPOPROTEIN E-MEDIATED METABOLISM, Journal of Biological Chemistry, vol.277, issue.13, pp.11064-11068, 2002.
DOI : 10.1074/jbc.M111222200

V. Ram, Therapeutic role of peroxisome proliferator-activated receptors in obesity, diabetes and inflammation, Prog Drug Res, vol.60, pp.96-132, 2003.
DOI : 10.1007/978-3-0348-8012-1_3

U. Risérus, D. Sprecher, T. Johnson, E. Olson, S. Hirschberg et al., Activation of Peroxisome Proliferator-Activated Receptor (PPAR)?? Promotes Reversal of Multiple Metabolic Abnormalities, Reduces Oxidative Stress, and Increases Fatty Acid Oxidation in Moderately Obese Men, Diabetes, vol.57, issue.2, pp.332-339, 2008.
DOI : 10.2337/db07-1318

L. Sanderson, M. Boekschoten, B. Desvergne, M. Müller, and S. Kersten, Transcriptional profiling reveals divergent roles of PPAR?? and PPAR??/?? in regulation of gene expression in mouse liver, Physiological Genomics, vol.41, issue.1, pp.42-52, 2010.
DOI : 10.1152/physiolgenomics.00127.2009

T. Tanaka, J. Yamamoto, S. Iwasaki, H. Asaba, H. Hamura et al., Activation of peroxisome proliferator-activated receptor ?? induces fatty acid ??-oxidation in skeletal muscle and attenuates metabolic syndrome, Proceedings of the National Academy of Sciences, vol.100, issue.26, pp.15924-15929, 2003.
DOI : 10.1073/pnas.0306981100

J. Van-der-veen, J. Kruit, R. Havinga, J. Baller, G. Chimini et al., Reduced cholesterol absorption upon PPAR?? activation coincides with decreased intestinal expression of NPC1L1, The Journal of Lipid Research, vol.46, issue.3, pp.526-534, 2005.
DOI : 10.1194/jlr.M400400-JLR200

H. Vosper, L. Patel, T. Graham, G. Khoudoli, A. Hill et al., The Peroxisome Proliferator-activated Receptor ?? Promotes Lipid Accumulation in Human Macrophages, Journal of Biological Chemistry, vol.276, issue.47, pp.44258-44265, 2001.
DOI : 10.1074/jbc.M108482200

W. Wahli, A gut feeling of the PXR, PPAR and NF-??B connection, Journal of Internal Medicine, vol.6, issue.6, pp.613-619, 2008.
DOI : 10.1126/science.1116221

J. Wallace, M. Schwarz, P. Coward, J. Houze, J. Sawyer et al., Effects of peroxisome proliferator-activated receptor ??/?? agonists on HDL-cholesterol in vervet monkeys, The Journal of Lipid Research, vol.46, issue.5, pp.1009-1016, 2005.
DOI : 10.1194/jlr.M500002-JLR200

J. Welch, M. Ricote, T. Akiyama, F. Gonzalez, and C. Glass, PPAR?? and PPAR?? negatively regulate specific subsets of lipopolysaccharide and IFN-?? target genes in macrophages, Proceedings of the National Academy of Sciences, vol.100, issue.11, pp.6712-6717, 2003.
DOI : 10.1073/pnas.1031789100